ECM Weekly (3 May 2020) - JD.com, Hangzhou Tigermed, Peijia Medical, Central China New Life
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
The Australia placement streak continues as we get another four equity raises this week, out of which, three were about A$1bn or more. National Australia Bank (NAB AU), Charter Hall Retail Reit (CQR AU), and Lendlease Group (LLC AU) held well above their deal price while Newcrest Mining (NCM AU) broke deal price on the first day of trading post-placement.
- National Australia Bank Placement - Risk Reward Favorable but Outlook Still Uncertain
- Charter Hall Retail REIT Placement - Large Dilution but Its Not All Bad
- Lendlease Group Placement - Big Deal, Different Narrative, but Well-Positioned for a Recovery
- Newcrest Mining Placement - Increased Exposure Will Likely Be Accretive to Earnings
Hong Kong's ECM market is also ramping up. We finally got news that JD.com Inc (ADR) (JD US) has filed confidentially for a secondary listing and, as per media reports, the deal size will be somewhere between US$2 - 4bn. Sumeet Singh shared his early thoughts on the deal in:
Other upcoming listings include Central China New Life (CCNL HK) which has already gotten approval from HKEX and will likely launch its US$300m bookbuild this coming week. Peijia Medical (1740651D CH) got approved as well. We also covered Hangzhou Tigermed Consulting (300347 CH) A/H listing. The company filed its draft prospectus last week. The team share thoughts on the listings in:
- Peijia Medical (沛嘉医疗) Pre-IPO: Deserves Valuation Premium for the TAVR Late Comer
- Central China New Life (建业新生活) Pre-IPO - Expanding Focus Beyond Property Management
- Tigermed (泰格医疗) A+H Listing: Hot Deal of the Best China Clinical-CRO Play
Beyond that, there were also two new filings. Nongfu Spring, a Chinese bottled water and beverage company, which was said to be seeking US$1bn filed its draft prospectus, and, Ocumension Therapeutics, a Shanghai Biopharma which has a portfolio of 16 ophthalmology drugs, is also looking to list.
We will be covering these IPOs soon.
Accuracy Rate:
Our overall accuracy rate is 73.4% for IPOs and 65.4% for Placements
(Performance measurement criteria is explained at the end of the note)
New IPO filings this week
- Nongfu Spring(~US$1bn, Hong Kong)
- Ocumension Therapeutics (US$100m, Hong Kong)
Below is a snippet of our IPO tool showing upcoming events for the next week. The IPO tool is designed to provide readers with timely information on all IPO related events (Book open/closing, listing, initiation, lock-up expiry, etc) for all the deals that we have worked on. You can access the tool here or through the tools menu.
News on Upcoming IPOs
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
- ECM Weekly (24 May 2020) - NetEase and JD Homecoming, Legend Biotech, Nongfu Spring, Yeahka24 May 2020
- ECM Weekly (17 May 2020) -Dada Nexus, Kintor Pharma, Yeahka, Archosaur Games17 May 2020
- ECM Weekly (10 May 2020) - Kingsoft Cloud, NetEase, Central China New Life, Peijia Medical, Kintor,10 May 2020
- ECM Weekly (3 May 2020) - JD.com, Hangzhou Tigermed, Peijia Medical, Central China New Life03 May 2020
- JD.com HK Listing - Early Look - Getting the Ball Rolling29 Apr 2020
- Peijia Medical (沛嘉医疗) Pre-IPO: Deserves Valuation Premium for the TAVR Late Comer28 Apr 2020
- ECM Weekly (26 Apr 2020) - Kingsoft Cloud, WeDoctor, Akesobio, Kotak Mahindra Bank26 Apr 2020